DURECT Corporation (DRRX) News
Filter DRRX News Items
DRRX News Results
|Loading, please wait...|
DRRX News Highlights
- DRRX's 30 day story count now stands at 5.
- Over the past 7 days, the trend for DRRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about DRRX are BEAT and ENTA.
Latest DRRX News From Around the Web
Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.
Q3 2023 DURECT Corp Earnings Call
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update.
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call and webcast with investors to discuss financial results and provide a corpor
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.
Lucid Motors stock is falling after Cantor Fitzgerald analysts downgraded LCID shares and cut their price target following its Q3 earnings.
Durect stock is taking a beating on Wednesday as DRRX investors react to results from a Phase 2b clinical trial of larsucosterol.
Sleep Number stock is falling on Wednesday as investors in SNBR react to the company missing EPS and revenue estimates for Q3.
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced topline results from its AHFIRM trial, a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of larsucosterol in 307 patients with severe alcohol-associated hepatitis (AH). Topline data from AHFIRM showed
Let’s talk about penny stocks. These are equities that trade for less than $5 per share, at the very bottom of the price range. While they are priced that low for a reason – and the reasons may vary – a low price in itself doesn’t mean that the stock’s fundamentals are sour. Smart investors can find some true bargains among penny stocks and set themselves up for outsized gains. The opportunity is linked to a simple question: Why is the company’s stock priced so low? If the answer is mainly benig